TJN 598

Drug Profile

TJN 598

Latest Information Update: 01 Jun 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tsumura
  • Class Anti-inflammatories
  • Mechanism of Action Transforming growth factor beta1 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glomerulonephritis

Most Recent Events

  • 20 Mar 2005 Discontinued - Phase-II for Glomerulonephritis in Japan (PO)
  • 20 Oct 2004 Phase-II clinical trials in Glomerulonephritis in Japan (PO)
  • 20 Feb 2004 Phase-I clinical trials in Glomerulonephritis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top